These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 30307465)

  • 1. Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach.
    Galot R; Le Tourneau C; Guigay J; Licitra L; Tinhofer I; Kong A; Caballero C; Fortpied C; Bogaerts J; Govaerts AS; Staelens D; Raveloarivahy T; Rodegher L; Laes JF; Saada-Bouzid E; Machiels JP
    Ann Oncol; 2018 Dec; 29(12):2313-2327. PubMed ID: 30307465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of second-line treatments of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    El Rassy E; Assi T; Bakouny Z; El Karak F; Pavlidis N; Ghosn M
    Future Oncol; 2019 Mar; 15(8):909-923. PubMed ID: 30669875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is high-risk cutaneous squamous cell carcinoma of the head and neck a suitable candidate for current targeted therapies?
    Zilberg C; Lee MW; Kraitsek S; Ashford B; Ranson M; Shannon K; Iyer NG; Ch'ng S; Low TH; Palme C; Clark J; Gupta R; Yu B
    J Clin Pathol; 2020 Jan; 73(1):17-22. PubMed ID: 31300530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic role of epiregulin/amphiregulin expression in recurrent/metastatic head and neck cancer treated with cetuximab.
    Kogashiwa Y; Inoue H; Kuba K; Araki R; Yasuda M; Nakahira M; Sugasawa M
    Head Neck; 2018 Nov; 40(11):2424-2431. PubMed ID: 30302873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes of platinum-based chemotherapy plus cetuximab for recurrent or metastatic squamous cell carcinoma of the head and neck: comparison between platinum-sensitive and platinum-resistant patients.
    Sato H; Tsukahara K; Okamoto I; Katsube Y; Shimizu A; Kondo T; Hanyu K; Fushimi C; Okada T; Miura K
    Acta Otolaryngol; 2019 Feb; 139(2):201-205. PubMed ID: 30794080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarker threshold adaptive designs for survival endpoints.
    Diao G; Dong J; Zeng D; Ke C; Rong A; Ibrahim JG
    J Biopharm Stat; 2018; 28(6):1038-1054. PubMed ID: 29436940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survivin overexpression in head and neck squamous cell carcinomas as a new therapeutic target (Review).
    Frassanito MA; Saltarella I; Vinella A; Muzio LL; Pannone G; Fumarulo R; Vacca A; Mariggiò MA
    Oncol Rep; 2019 May; 41(5):2615-2624. PubMed ID: 30896830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
    Lee JH; Heo SG; Ahn BC; Hong MH; Cho BC; Lim SM; Kim HR
    Cancer Med; 2021 Oct; 10(20):7012-7020. PubMed ID: 34528763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic burden of chemotherapy-treated recurrent and/or metastatic squamous cell carcinoma of the head and neck in France: real-world data from the permanent sample of national health insurance beneficiaries.
    Lafuma A; Cotté FE; Le Tourneau C; Emery C; Gaudin AF; Torreton E; Gourmelen J; Bonastre J
    J Med Econ; 2019 Jul; 22(7):698-705. PubMed ID: 30895832
    [No Abstract]   [Full Text] [Related]  

  • 10. Highlights in Head and Neck Cancer.
    Chau NG; Tishler RB; Haddad RI
    JAMA Oncol; 2017 Apr; 3(4):441-442. PubMed ID: 27893016
    [No Abstract]   [Full Text] [Related]  

  • 11. Cancer stem cell biomarkers for head and neck squamous cell carcinoma: A bioinformatic analysis.
    Xiao M; Liu L; Zhang S; Yang X; Wang Y
    Oncol Rep; 2018 Dec; 40(6):3843-3851. PubMed ID: 30542719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current applications and challenges of circulating tumor DNA (ctDNA) in squamous cell carcinoma of the head and neck (SCCHN).
    Galot R; Machiels JH
    Cancer Treat Rev; 2020 Apr; 85():101992. PubMed ID: 32092618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
    Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
    Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy in recurrent and or metastatic squamous cell carcinoma of the head and neck.
    Saada-Bouzid E; Peyrade F; Guigay J
    Curr Opin Oncol; 2019 May; 31(3):146-151. PubMed ID: 30893146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microenvironment-driven intratumoral heterogeneity in head and neck cancers: clinical challenges and opportunities for precision medicine.
    Van den Bossche V; Zaryouh H; Vara-Messler M; Vignau J; Machiels JP; Wouters A; Schmitz S; Corbet C
    Drug Resist Updat; 2022 Jan; 60():100806. PubMed ID: 35121337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Personalized Biomarker-Based Umbrella Trial for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: KCSG HN 15-16 TRIUMPH Trial.
    Keam B; Hong MH; Shin SH; Heo SG; Kim JE; Ahn HK; Lee YG; Park KU; Yun T; Lee KW; Kim SB; Lee SC; Kim MK; Cho SH; Oh SY; Park SG; Hwang S; Nam BH; Kim S; Kim HR; Yun HJ;
    J Clin Oncol; 2024 Feb; 42(5):507-517. PubMed ID: 37699162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic score in patients with recurrent or metastatic carcinoma of the head and neck treated with cetuximab and chemotherapy.
    Magnes T; Melchardt T; Weiss L; Mittermair C; Neureiter D; Klieser E; Gampenrieder S; Moser G; Gaggl A; Greil R; Egle A
    PLoS One; 2017; 12(7):e0180995. PubMed ID: 28686697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized Phase II Study of Cabazitaxel Versus Methotrexate in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-Based Therapy.
    Machiels JP; Van Maanen A; Vandenbulcke JM; Filleul B; Seront E; Henry S; D'Hondt L; Lonchay C; Holbrechts S; Boegner P; Brohee D; Dequanter D; Louviaux I; Sautois B; Whenham N; Berchem G; Vanderschueren B; Fontaine C; Schmitz S; Gillain A; Schoonjans J; Rottey S
    Oncologist; 2016 Dec; 21(12):1416-e17. PubMed ID: 27903924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
    Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
    Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck.
    Le Tourneau C; Siu LL
    Curr Opin Oncol; 2008 May; 20(3):256-63. PubMed ID: 18391623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.